David Coman, CEO, BGBx, explains how the firm's rebranding reflects a broader shift in biopharma commercialization, where integrating consulting, communications, and a three-dimensional science framework is increasingly necessary for companies.
David Coman
Advertisement
David Coman is Chief Executive Officer at BGBx, where he leads the organization’s strategic direction, growth, innovation, and client impact across the life sciences industry. He focuses on helping organizations navigate an increasingly complex healthcare landscape by aligning data, technology, and commercial strategy to drive measurable business outcomes.
Articles by David Coman
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
The New Healthy Aging Imperative and What It Means for Pharma
2
EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval
3
Reading Between the Lines: Closing the T1D Misdiagnosis Gap
4
Why ‘Fully Staffed’ Field Teams Still Miss Revenue Targets—and How Pharma Can Fix It
5